Newsmeme!
Discover News you didn't know existed
Gefitnib is as effective a second-line treatment as docetaxel for patients with non-small cell* lung cancer. The INTEREST study, published in an Article in this week's edition of The Lancet, thus establishes gefitinib as a valid treatment option for people with this condition. The study was written by Dr Edward Kim, M. D. Anderson Cancer Center, Houston, Texas, USA and colleagues.
No tags found at this time. Be the first to tag this news item, learn more.
No related news stories found.
None found at this time.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |